Key result
Co-prescription of CYP3A4-mediated antipsychotic drugs was associated with a increased risk of QTc prolongation compared to non-CYP3A4-mediated drugs in patients with schizophrenia.
Why the study?
Does the co-prescription of CYP3A4-mediated antipsychotics increase the risk of QTc prolongation in patients with schizophrenia?
Cohort (n=1,437)
Yes
Does the co-prescription of CYP3A4-mediated antipsychotics increase the risk of QTc prolongation in patients with schizophrenia?
Co-prescription of CYP3A4-mediated antipsychotics and female gender are significant risk factors for QTc prolongation in patients with schizophrenia.
Answers are grounded in this paper and cite their sources.
May warrant QTc monitoring with CYP3A4 antipsychotics in schizophrenia; leaves open causality from observational data.
Objective: To identify the effects of antipsychotics on QTc prolongation in light of age, gender, antipsychotic combination pattern, antipsychotic doses and cytochrome P450 (CYP) mediation, using large database describing the antipsychotic treatment of patients with schizophrenia in Japan. Methods: Using database of 4176 patients with schizophrenia discharged between April 2004 and March 2005 and receiving outpatient treatment from 526 psychiatric hospitals in Japan. Of the patients, 1437 were included for the analysis. These patients were classified into three groups according to the antipsychotic CPZ-equivalent doses that they received (low, 1 - 299 mg; middle, 300 - 999 mg; and high, ≥1000 mg). QTc intervals ≥ 440 msec were considered prolonged. We reviewed all the package inserts of the antipsychotics used from the website of Pharmaceuticals and Medical Devices Agency. Results: The mean QTc interval of the total patient group was 410.4 ± 23.3 msec. The females had significantly higher QTc values than the males (414.5 ± 24.0 vs. 406.8 ± 22.2 msec, respectively; p 0.05). Logistic regression analysis revealed that female gender (odds ratio [OR] = 1.83; 95% CI: 1.28 - 2.56), CYP3A4-metabolized drugs (OR 1.56; 95% CI: 1.05 - 2.30) were associated with an increased risk of QTc prolongation. Conclusion: The co-prescription of CYP3A4-mediated antipsychotic drugs should be carefully considered in females due to potential risk of QTc prolongation. Further studies of the cardiovascular safety of antipsychotics are warranted in patients receiving multiple medications.
No takes yet. Share an insight, caveat, or question.
Ikeno et al. (2014) conducted a cohort in Schizophrenia (n=1,437). CYP3A4-mediated antipsychotic drugs vs. Non-CYP3A4-mediated antipsychotic drugs was evaluated on QTc prolongation (≥ 440 msec) (OR 1.56, 95% CI 1.05 - 2.30, p=0.026). Co-prescription of CYP3A4-mediated antipsychotic drugs was associated with a increased risk of QTc prolongation compared to non-CYP3A4-mediated drugs in patients with schizophrenia.
Synapse has enriched 10 related papers. Consider them for comparative context: